Syracuse

In vivo targeting and multimodal imaging of cerebral amyloid-β aggregates using hybrid GdF 3 nanoparticles

Archive ouverte

Lerouge, Frédéric | Ong, Elodie | Rositi, Hugo | Mpambani, Francis | Berner, Lise-Prune | Bolbos, Radu | Olivier, Cécile | Peyrin, Françoise | Apputukan, Vinu, K | Monnereau, Cyrille | Andraud, Chantal | Chaput, Fréderic | Berthezène, Yves | Braun, Bettina | Jucker, Mathias | Åslund, Andreas Ko | Nyström, Sofie | Hammarström, Per | R Nilsson, K Peter | Lindgren, Mikael | Wiart, Marlène | Chauveau, Fabien | Parola, Stephane

Edité par CCSD ; Future Medicine -

International audience. Aim: To propose a new multimodal imaging agent targeting amyloid-β (Aβ) plaques in Alzheimer’s disease. Materials & methods: A new generation of hybrid contrast agents, based on gadolinium fluoride nanoparticles grafted with a pentameric luminescent-conjugated polythiophene, was designed, extensively characterized and evaluated in animal models of Alzheimer’s disease through MRI, two-photon microscopy and synchrotron x-ray phase-contrast imaging. Results & conclusion: Two different grafting densities of luminescent-conjugated polythiophene were achieved while preserving colloidal stability and fluorescent properties, and without affecting biodistribution. In vivo brain uptake was dependent on the blood–brain barrier status. Nevertheless, multimodal imaging showed successful Aβ targeting in both transgenic mice and Aβ fibril-injected rats.

• Description
• Sujet/Public
• Outil
• Outil d'anticipation
• Mémoire et thèse
• Gestion